ID   Rj2.2.5
AC   CVCL_3414
SY   RJ2.2.5; RJ-2.2.5; RJ 2.2.5; RJ2.25; Raji 2.2.5
DR   CLDB; cl7125
DR   cancercelllines; CVCL_3414
DR   CLS; 300360
DR   GEO; GSM1602239
DR   GEO; GSM1602240
DR   GEO; GSM1602245
DR   GEO; GSM1602246
DR   ICLC; HTL02002
DR   Wikidata; Q54950516
RX   PubMed=1538137;
RX   PubMed=1852002;
RX   PubMed=2511169;
RX   PubMed=6403646;
RX   PubMed=8402893;
RX   PubMed=8441650;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/r/cell-lines-detail-28.html
WW   https://emoryott.technologypublisher.com/tech/CIITA_Deficient_Human_B_Cell_Line
CC   Population: African; Nigerian.
CC   Characteristics: Deficient in expression of HLA class II antigens.
CC   HLA typing: A*03:01:01; B*15:10:01; C*03:04:02,04:01:01; DPB1*01:01:01; DQA1*01:05:01,05:01:01; DQB1*02:01:01,05:01:01; DRB1*03:01:01,10:01:01 (CLS=300360).
CC   Sequence variation: Gene deletion; HGNC; 7067; CIITA; Zygosity=Heterozygous (PubMed=8402893).
CC   Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7067; CIITA; Unexplicit; Major internal deletion; Zygosity=Heterozygous (PubMed=8402893).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Transformant: NCIt; C44386; Gamma radiation.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Derived from site: In situ; Bone, jaw, maxilla; UBERON=UBERON_0002397.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): CLS=300360
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 13
ST   D16S539: 8,11
ST   D18S51: 17
ST   D21S11: 28,31
ST   D3S1358: 15,16
ST   D5S818: 10
ST   D7S820: 10
ST   D8S1179: 14,15
ST   FGA: 19,27
ST   Penta D: 3.2,9
ST   Penta E: 5,13
ST   TH01: 6,7
ST   TPOX: 8,13
ST   vWA: 16,19
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0511 ! Raji
SX   Male
AG   11Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 24
//
RX   PubMed=1538137; DOI=10.4049/jimmunol.148.5.1576;
RA   Seidl C., Saraiya C., Osterweil Z., Fu Y.P., Lee J.S.;
RT   "Genetic complexity of regulatory mutants defective for HLA class II
RT   gene expression.";
RL   J. Immunol. 148:1576-1584(1992).
//
RX   PubMed=1852002; DOI=10.1073/pnas.88.10.4285;
RA   Benichou B., Strominger J.L.;
RT   "Class II-antigen-negative patient and mutant B-cell lines represent
RT   at least three, and probably four, distinct genetic defects defined by
RT   complementation analysis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:4285-4288(1991).
//
RX   PubMed=2511169; DOI=10.1016/0198-8859(89)90007-4;
RA   Hume C.R., Lee J.S.;
RT   "Congenital immunodeficiencies associated with absence of HLA class II
RT   antigens on lymphocytes result from distinct mutations in trans-acting
RT   factors.";
RL   Hum. Immunol. 26:288-309(1989).
//
RX   PubMed=6403646; DOI=10.1084/jem.157.3.1053;
RA   Accolla R.S.;
RT   "Human B cell variants immunoselected against a single Ia antigen
RT   subset have lost expression of several Ia antigen subsets.";
RL   J. Exp. Med. 157:1053-1058(1983).
//
RX   PubMed=8402893; DOI=10.1016/S0092-8674(05)80090-X;
RA   Steimle V., Otten L.A., Zufferey M., Mach B.;
RT   "Complementation cloning of an MHC class II transactivator mutated in
RT   hereditary MHC class II deficiency (or bare lymphocyte syndrome).";
RL   Cell 75:135-146(1993).
//
RX   PubMed=8441650; DOI=10.1093/nar/21.3.381;
RA   Ombra M.N., Perfetto C., Autiero M., Anzisi A.M., Pasquinelli R.,
RA   Maffei A., Del Pozzo G., Guardiola J.;
RT   "Reversion of a transcriptionally defective MHC class II-negative
RT   human B-cell mutant.";
RL   Nucleic Acids Res. 21:381-386(1993).
//